Sylvester Comprehensive Cancer Center is building a dedicated Myeloma Research Institute. C. Ola Landgren, who joined Sylvester two years ago, will be the director.
Data from a subset of patients in an ongoing phase I study of Poseida Therapeutics’s lead program P-BCMA-ALLO1 showed that three of the five (60%) patients with relapsed/refractory multiple myeloma who had progressed following BCMA-targeted therapy achieved clinical responses with P-BCMA-ALLO1. In addition, this investigational treatment was well-tolerated.
